antisens
antimicrobi
therapeut
synthet
oligom
silenc
express
specif
gene
specif
confer
advantag
broadspectrum
antibiot
avoid
unintend
effect
commens
bacteria
sequencespecif
short
length
antisens
antimicrobi
also
pose
littl
risk
human
gene
express
antisens
antimicrobi
platform
technolog
rapidli
design
synthes
target
almost
microb
reduc
drug
discoveri
time
provid
flexibl
ration
approach
drug
develop
recent
work
shown
antisens
technolog
potenti
address
antibioticresist
crisi
sinc
resist
mechan
standard
antibiot
appar
effect
antisens
antimicrobi
describ
current
report
antisens
antimicrobi
target
virus
parasit
bacteria
antisens
antimicrobi
short
singlestrand
oligom
mimic
structur
dna
rna
bind
specif
complementari
rna
target
organ
microorgan
antisens
therapeut
bind
complementari
mrna
inhibit
translat
promot
degrad
target
mrna
although
mani
chemic
structur
design
antisens
technolog
focu
four
structur
type
recent
gain
attent
figur
phosphorothio
lock
nucleic
acid
peptid
nucleic
acid
phosphorodiamid
morpholino
oligom
plu
other
structur
modif
four
phosphorothio
oligodeoxynucleotid
soligo
analogu
phosphodiest
oligonucleotid
sulfur
atom
instead
one
nonbridg
oxygen
atom
phosphat
linkag
modif
increas
stabil
oligonucleotid
nucleas
soligo
bind
complementari
mrna
activ
rnase
h
degrad
target
mrna
figur
soligo
fomivirsen
brand
name
vitraven
fdaapprov
antisens
therapeut
target
microorgan
fomivirsen
approv
treatment
cytomegalovirusinduc
retin
lock
nucleic
acid
lna
oxyphosphorothio
analogu
cmethylen
bridg
lock
ribos
ring
endo
conform
bridg
nucleic
acid
bna
analogu
lna
shown
figur
lna
bna
oligom
stabl
nucleas
high
affin
dna
rna
exhibit
low
toxic
also
may
act
rnase
h
degrad
target
mrna
peptid
nucleic
acid
pna
construct
attach
base
modifi
polyamid
backbon
resist
nucleas
proteas
act
block
translat
pna
uncharg
part
account
high
affin
rna
phosphorodiamid
morpholinooligom
pmo
compris
base
dna
modifi
linkag
base
morpholin
ring
substitut
ribos
dimethyl
amin
substitut
one
nonbridg
oxygen
atom
phosphat
linkag
pmo
nearli
net
neutral
charg
water
solubl
resist
nucleas
pmo
act
steric
block
initi
translat
activ
rnase
h
degrad
pmoplu
analogu
pmo
posit
charg
piperazinyl
phosphorodiamid
linkag
need
new
antimicrobi
never
greater
due
limit
select
avail
therapeut
prolifer
multidrug
resist
organ
recent
develop
antisens
inhibit
microbi
target
shown
great
potenti
address
urgent
need
present
entir
new
excit
paradigm
drug
develop
antisens
technolog
use
molecular
tool
select
silenc
rna
identif
gene
function
substitut
knockout
mutat
compil
focus
antisens
technolog
develop
therapi
microbi
infect
review
recent
use
antisens
technolog
antivir
antiparasit
antibacteri
futur
direct
platform
technolog
influenza
viru
earli
work
antisens
therapeut
ebola
viru
ebov
show
therapeut
treatment
combin
two
pmobas
oligom
increas
surviv
infect
mice
guinea
pig
test
rhesu
monkey
model
infect
show
antisens
therapi
increas
surviv
depend
dose
reduc
viremia
inflamm
liver
damag
recent
warren
et
al
report
therapeut
treatment
one
oligom
alon
target
ebov
protein
protect
rhesu
monkey
lethal
ebov
infect
particularli
interest
develop
antisens
oligom
call
pmoplu
requir
cation
membranepenetr
peptid
efficaci
instead
posit
charg
ad
molecular
backbon
molecul
although
mechan
unknown
posit
charg
backbon
enabl
efficaci
appear
enabl
membran
penetr
provid
intracellular
access
replic
viru
anoth
relat
hemorrhag
viru
marburg
viru
marv
also
suscept
antisens
inhibit
pmoplu
target
marv
nucleoprotein
major
nucleoprotein
involv
rna
encapsid
interfer
interferon
signal
show
dosedepend
surviv
rate
nonhuman
model
infect
pmoplu
also
test
safeti
pharmacokinet
human
intraven
rang
mg
kg
day
result
show
signific
effect
safeti
endpoint
evalu
although
nonseri
advers
event
report
particip
chikungunya
viru
chikv
mosquitoborn
zoonot
rna
viru
experienc
resurg
last
decad
larg
outbreak
seen
africa
area
southern
asia
recent
work
two
antichikv
phosphorodiamid
morpholino
oligom
cpmo
design
bind
two
open
read
frame
viral
genom
rna
author
show
target
suppress
viral
replic
human
cell
hela
significantli
lower
viral
titer
tissu
use
neonat
mous
model
infect
importantli
cytotox
seen
hela
cell
pmoinduc
toxic
neonat
mice
enteroviru
main
caus
pathogen
hand
foot
mouth
diseas
impact
felt
worldwid
primarili
asia
recent
work
describ
antisens
phosphorothio
oligonucleotid
show
protect
effect
vitro
vivo
treatment
infect
tissu
cultur
cell
reduc
viral
replic
viral
protein
express
cell
death
administ
vivo
use
mous
model
infect
protect
mice
reduc
viral
replic
select
organ
hepat
b
viru
hbv
carri
approxim
million
peopl
worldwid
million
die
annual
due
hepatocellular
carcinoma
chronic
hbv
liver
failur
hbv
gene
encod
three
envelop
protein
compris
hepat
b
surfac
antigen
hbsag
hbcag
encod
c
gene
found
core
nucleocapsid
precursor
secret
hbeag
deng
et
al
synthes
lock
nucleic
acid
target
either
hbv
gene
c
gene
sc
doubl
gene
encapsul
liposom
treat
hbv
transgen
mice
result
show
three
treatment
decreas
hbv
dna
replic
dualtarget
sc
lna
show
greatest
reduct
furthermor
three
hbv
lna
reduc
number
hbsagposit
hbcagposit
liver
cell
measur
immunohistochemistri
result
taken
find
obviou
toxic
suggest
lna
warrant
consider
therapi
hbv
work
billioud
et
al
also
target
hbsag
product
use
omethoxyethylmodifi
phosphorothio
enhanc
potenc
stabil
hepatoma
cultur
hbsag
oligom
reduc
hbv
rna
dna
well
hbsag
hbeag
protein
administ
hbv
transgen
mice
hbsag
oligom
decreas
hbsag
hbeag
serum
level
within
first
day
treatment
remain
origin
level
three
week
hepat
c
viru
hcv
affect
million
peopl
major
caus
agent
chronic
liver
diseas
cirrhosi
hepatocellular
carcinoma
miravirsen
bdoxylnamodifi
phosphorothio
antisens
oligonucleotid
complementari
part
liverspecif
mirna
express
hepatocyt
import
factor
hcv
viru
replic
recent
ottosen
et
al
show
treatment
miravirsen
addit
antivir
effect
use
conjunct
inhibitor
nonstructur
hcv
protein
importantli
miravirsen
alon
activ
hcv
replicon
resist
inhibitor
current
human
receiv
miravirsen
phase
clinic
trial
exhibit
prolong
decreas
plasma
level
although
miravirsen
appear
effect
clinic
trial
commerci
fate
unknown
particularli
sinc
introduct
effect
small
molecul
inhibitor
hcv
sovaldi
harvoni
parasit
diseas
continu
affect
hundr
million
peopl
worldwid
current
therapi
outdat
deleteri
side
effect
antiparasit
drug
discoveri
fraught
difficulti
mainli
biolog
complex
parasit
associ
physiolog
chang
parasit
life
cycl
complic
matter
resist
also
major
problem
recent
studi
genespecif
antisens
therapeut
parasit
infect
pave
way
develop
malariacaus
parasit
plasmodium
falciparum
replic
insid
red
blood
cell
infect
estim
million
peopl
per
year
uniqu
featur
p
falciparum
genom
compris
base
pair
distinct
human
genom
make
p
falciparum
genom
great
candid
target
sequencespecif
inhibitor
kolevzon
et
al
util
pna
alter
gene
express
p
falciparum
pna
target
ortholog
conserv
nucleoporin
essenti
viabil
p
falciparum
mean
facilit
solubl
permeabl
cell
membran
pna
conjug
polydlysin
result
show
pna
reach
nucleu
downregul
express
decreas
viabil
parasit
cultur
differ
group
target
essenti
gene
p
falciparum
involv
apicoplast
biogenesi
pfdxr
membran
biosynthesi
pfpmt
drugmetabolit
transport
pfcrt
peptideconjug
pmo
ppmo
octaguanidiniumconjug
pmo
vmo
construct
test
cultur
exposur
parasit
conjug
decreas
target
rna
express
inhibit
parasit
viabil
insid
red
blood
cell
notabl
author
abl
restor
chloroquin
sensit
resist
strain
p
falciparum
treat
pfcrtvmo
chaga
diseas
caus
parasit
trypanosoma
cruzi
histor
found
rural
latin
america
diseas
affect
approxim
eight
million
peopl
infect
develop
cardiomyopathi
hashimoto
et
al
util
phosphorothio
antisens
oligo
soligo
target
cruzi
inositol
receptor
tcip
r
mrna
tcip
r
essenti
protein
requir
parasit
invas
host
cell
result
show
antisens
oligom
antisens
decreas
level
tcip
r
cruzi
trypomastigot
moreov
decreas
tcip
r
correspond
inhibit
invas
cruzi
albino
cell
hela
cell
hashimoto
et
al
also
test
morpholino
oligom
target
splice
site
pretcip
r
mrna
oligom
bound
splice
leader
acceptor
region
inhibit
matur
target
mrna
exposur
parasit
impair
growth
cultur
decreas
invas
host
cell
mechan
action
confirm
inhibit
transsplic
use
realtim
rtpcr
toxoplasma
gondii
oblig
intracellular
zoonot
parasit
infect
one
third
world
human
popul
effect
medicin
safe
effect
vaccin
gondii
howev
result
recent
report
suggest
antisens
ppmo
could
develop
therapeut
treatment
ppmo
target
mrna
thought
import
intracellular
growth
surviv
reduc
express
surviv
growth
gondii
fibroblast
monocyt
vitro
efficaci
antibiot
resist
escal
worldwid
problem
urgent
need
new
effect
antimicrobi
usual
strategi
screen
librari
compound
chemic
modifi
exist
antibiot
produc
diminish
return
recent
year
particularli
antibiot
gram
neg
pathogen
altern
strategi
design
genespecif
oligom
specif
target
singl
pathogen
approach
nearli
elimin
significantli
reduc
time
requir
discoveri
new
antimicrobi
broaden
rang
potenti
avail
target
gene
known
base
sequenc
bacterium
synthet
dna
analogu
design
shown
inhibit
growth
bacteria
sinc
signific
improv
made
along
way
aid
identif
essenti
gene
number
sequenc
genom
perhap
import
improv
attach
cellpenetr
peptid
cpp
cell
wall
bacteria
nearli
impenetr
high
molecular
weight
oligom
deliveri
synthet
antisens
oligom
bacteri
cytoplasm
requir
attach
anoth
compound
penetr
bacteri
cell
wall
recent
report
use
antisens
oligom
coupl
cpp
often
sequenc
altern
cation
nonpolar
amino
acid
wesolowski
et
al
describ
cpppmo
conjug
target
escherichia
coli
gyra
highli
conserv
gene
found
across
multipl
bacteri
speci
author
test
sensit
varieti
gramposit
gramneg
bacteri
strain
cpppmo
result
show
gyra
cpppmo
reduc
viabil
enterococcu
faecali
staphylococcu
aureu
pseudomona
aeruginosa
streptococcu
pneumonia
gyras
also
target
pyogen
use
cpppna
result
show
reduct
gyra
mrna
express
inhibit
growth
addit
cpppna
synergist
variou
standard
antibiot
recent
liang
et
al
describ
peptideconjug
pna
ppna
target
ftsz
aureu
requir
cell
divis
result
show
ftsz
ppna
inhibit
growth
cultur
concentrationdepend
manner
decreas
express
ftsz
mrna
deliveri
antisens
oligom
bacteria
even
challeng
address
intracellular
pathogen
bacteria
oligom
may
transloc
host
pathogen
membran
earli
work
target
intracellular
bacteria
found
modifi
ppmo
inhibit
growth
intracellular
salmonella
recent
work
abushahba
et
al
compar
efficaci
variou
cpp
deliv
payload
intracellular
pathogen
listeria
monocytogen
author
examin
five
differ
cpp
conjug
pna
target
rna
polymeras
subunit
rpoa
result
show
argininerich
peptid
altern
nonpolar
amino
acid
rxr
xb
describ
previous
mellby
et
al
effect
deliv
antisens
oligom
reduc
viabil
l
monocytogen
report
also
show
rxr
pna
effect
oligom
test
vivo
use
caenorhabd
elegan
model
infect
cppconjug
pna
also
effect
facult
intracellular
pathogen
brucella
sui
caus
agent
brucellosi
affect
swine
pass
human
report
rajasekaran
et
al
show
pna
target
pola
bactericid
pure
cultur
howev
infect
macrophag
potent
target
pna
asd
dnag
gene
involv
cell
wall
synthesi
chromosom
replic
respect
differ
potenc
pna
pure
cultur
macrophag
attribut
differ
avail
nutrient
growth
two
differ
environ
consider
number
report
show
vitro
efficaci
synthet
antisens
antibacteri
past
year
far
fewer
report
show
efficaci
anim
model
infect
first
report
vivo
efficaci
show
pmo
without
conjug
peptid
target
essenti
gene
acpp
reduc
viabil
e
coli
mous
model
infect
subsequ
report
establish
vivo
efficaci
structur
type
synthet
oligom
shown
figur
use
anim
model
infect
varieti
pathogen
recent
report
describ
sawyer
et
al
recent
show
cpppmo
target
gyra
essenti
gene
requir
replic
reduc
viabil
staphylococcu
aureu
skin
wound
model
infect
addit
cpppmo
also
improv
heal
time
qualiti
result
suggest
cpppmo
may
also
effect
treatment
type
bacteri
skin
infect
anoth
report
efficaci
aureu
cpplna
target
ftsz
requir
cell
divis
test
mous
model
sepsi
result
show
singl
therapeut
dose
mgkg
ftsz
cpplna
reduc
bacteri
burden
log
variou
tissu
increas
surviv
geller
et
al
examin
efficaci
ppmo
target
acpp
two
differ
speci
acinetobact
includ
multidrug
resist
baumannii
ppmo
bactericid
vitro
importantli
also
effect
mous
model
pneumonia
result
show
bacteri
burden
proinflammatori
cytokin
lung
significantli
reduc
surviv
increas
depend
ppmo
dose
bacteri
speci
result
suggest
ppmo
may
therapeut
use
treat
pneumonia
administ
directli
lung
newer
altern
strategi
use
synthet
antisens
oligom
target
nonessenti
gene
requir
virul
confer
invas
biofilm
format
silenc
express
virul
gene
make
pathogen
less
fit
infect
advantag
target
nonessenti
gene
reduc
risk
resist
antibiot
resist
gene
exampl
virul
factor
target
synthet
antisens
oligom
strategi
target
antibiot
resist
gene
knock
express
antibiot
resist
would
restor
suscept
approv
antibiot
would
coadminist
oligom
p
aeruginosa
opportunist
pathogen
often
multidrug
resist
difficult
treat
greenberg
lab
recent
found
ppmo
target
gene
requir
biofilm
synthesi
quorum
sens
regul
altern
sigma
factor
inhibit
format
biofilm
reduc
exist
biofilm
form
p
aeruginosa
also
found
target
antibiot
resist
gene
p
aeruginosa
ppmo
restor
suscept
standard
antibiot
useless
without
ppmo
campylobact
jejuni
common
foodborn
pathogen
express
multidrug
efflux
pump
cmeabc
cmeabc
confer
resist
broad
rang
antibiot
oh
et
al
test
pna
target
variou
region
cmeabc
operon
identifi
two
pna
target
cmea
cmeb
restor
suscept
ciprofloxacin
erythromycin
goh
et
al
test
pna
target
meca
ftsz
methicillinresist
aureu
staphylococcu
pseudintermediu
determin
could
increas
suscept
oxacillin
result
show
pna
decreas
target
mrna
level
increas
suscept
oxacillin
vitro
other
also
target
meca
aureu
meng
et
al
util
phosphorothio
oligodeoxynucleotid
psodn
target
meca
deliv
anion
liposom
report
psodn
increas
suscept
oxacillin
vitro
mous
model
sepsi
meng
show
cotherapi
oxacillin
meca
psodn
reduc
bacteri
burden
blood
improv
surviv
lopez
et
al
target
aac
ib
enzym
found
mani
gramneg
clinic
isol
confer
resist
aminoglycosid
branch
nucleic
aciddna
hybrid
oligom
bna
nc
dna
coval
bound
cell
penetr
peptid
inhibit
activ
aac
ib
reduc
viabil
baumannii
cultur
contain
amikacin
vivo
protect
infect
galleria
mellonella
larva
administ
concomitantli
amikacin
current
work
lab
collabor
lab
test
ppmo
target
bla
produc
carbapenemas
particularli
danger
resist
gene
rapidli
spread
associ
antibiot
resist
gene
horizont
gene
transfer
mani
genera
bacteri
pathogen
render
useless
one
potent
class
antibiot
ppmo
restor
suscept
carbapenem
three
speci
gramneg
pathogen
test
e
coli
baumannii
p
aeruginosa
absenc
carbapenem
ppmo
effect
bacteri
growth
importantli
ppmo
effect
vivo
mous
model
sepsi
concomit
treatment
ppmo
meropenem
reduc
bacteremia
inflamm
increas
surviv
compar
treatment
ppmo
meropenem
alon
antisens
antimicrobi
come
long
way
past
three
decad
potenc
improv
point
mani
potent
standard
antimicrobi
vitro
resist
standard
antibiot
seem
effect
antisens
oligom
report
shown
signific
efficaci
anim
model
infect
use
dose
clinic
relev
rang
test
nonhuman
primat
model
recent
least
one
reach
clinic
test
think
futur
bright
excit
platform
technolog
great
potenti
address
urgent
need
new
strategi
discov
new
antimicrobi
blg
consult
sarepta
therapeut
inventor
numer
patent
patent
applic
involv
ppmo
ek
declar
compet
financi
interest
